NEW YORK--(BUSINESS WIRE)--
Lantern Pharma is excited to announce that it has been selected as a
"2018 TiE50 Finalist" for the prestigious TiE50 Awards Program
recognizing the world's most innovative tech startups. This awards
competition is part of TiE Inflect 2018, the world's largest conference
for tech entrepreneurs.
“We are honored to have been selected as a 2018 TiE50 Finalist for the
esteemed TiE50 Awards Program from more than 7000 companies all around
the world. Founded in 2013, Lantern Pharma is rethinking the cancer drug
development process, tailoring multiple promising precision drug
programs to the right subgroup of cancer patients through use of their
RADRTM platform (Response Algorithm for Drug Rescue and
Positioning). Right patient stratification is still considered by many
in pharma as the holy grail. Lantern is disrupting this using seamless
integration of relevant existing data, generation of new clean data
closely modeling real world evidence and very focused artificial
intelligence technology application to further model this data and
distill into meaningful information that can identify & stratify right
patients with high accuracy.
"Lantern is currently progressing 3 clinical stage drugs in using this
technology. Lantern also have a growing number of partnerships with
non-profits, and Academia. We look forward to sharing ideas with the
other Finalists, applicants and participants at TiE Inflect 2018.” -
Arun Asaithambi, Co-Founder
"TiE50 has become a global brand that attracts thousands of tech
startups worldwide. This year, we screened more than 7400 companies from
28 countries and selected the best-of-breed as our "2018 TiE50
Finalists". These companies are finalists in the ultimate runoff for the
50 winners. Our program has gained notoriety over the past decade as a
competition run with the highest level of integrity and vigorous
screening and judging by domain experts." - Kamal Anand, TiE50 Program
Chair
"As a 26-year not-for-profit dedicated to fostering entrepreneurship and
with a global footprint of half million entrepreneurs, enterprise
executives, and investment professionals, we pride in the fact that we
are one of very few competitions without any pay-to-play incentives." -
Ram K. Reddy, President, TiE Silicon Valley
About Lantern Pharma Inc
Lantern Pharma is a late clinical stage precision oncology company that
is using proprietary tech platform called RADR to identify drug specific
complex genetic signatures (potential CDX) for potential responders
identification and stratification with a high prediction accuracy to
conduct focused precision clinical trials. RADR is integrating any
existing clinical data, with data generated from wet-lab approach
closely modeling real world evidence/clinical trials and artificial
intelligence to identify genetic signatures and right responders.
Lantern's approach can improve success of the drug, lower developmental
costs and time many folds vs traditional drug developmental processes.
About TiE Inflect 2018:
TiE Inflect (previously TiEcon) is the world's largest conference for
entrepreneurs and intrapreneurs with participation from top technology
companies, leading venture capital firms, and global services providers.
TiEcon 2017 attracted 5400+ attendees from across the world - including
CEOs of established companies to first-time entrepreneurs creating new
companies, to leading investment professionals and corporate executives.
The conference was listed by Worth Magazine as one of the 10 best
conferences for ideas and entrepreneurship along with TED and the World
Economic Forum. For more information, please visit http://www.tieinflect.org.
About TiE:
The Indus Entrepreneurs (TiE) is a not-for-profit founded in 1992 in the
Silicon Valley by a group of successful entrepreneurs, corporate
executives, and senior professionals. TiE is the world's largest network
of tech entrepreneurs. We are a cohesive global network with a footprint
of half million entrepreneurs, enterprise executives, investment
professionals, and other accomplished individuals. We operate from 60
cities in 18 countries. http://www.tieeco.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425006862/en/
Lantern Pharma
Arun Asaithambi
arun@lanternpharma.com
Source: Lantern Pharma
Released April 25, 2018